Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japanese Kowa Signs Marketing Agreement With Solvay For Pitavastatin

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Kowa Pharmaceuticals Europe, a subsidiary of Japanese Kowa Company signed an agreement with Markham, Ontario-based Solvay Pharma under which Solvay will apply for Canadian government approval of Kowa's anti-cholesterol drug pitavastatin. Solvay Pharma, the Canadian subsidiary of Brussels, Belgium-based Solvay Group, will market the drug in Canada upon approval, expected as early as 2010, Kowa said. "KPE is granting Solvay exclusive rights to sell pitavastatin in Canada," Kowa spokesperson Naohisa Usui told PharmAsia News. Kowa estimates Canada's market for statin-based cholesterol drugs to be worth ¥160 billion ($1.48 billion) per year, and hopes that its product will achieve a 10 percent market share

You may also be interested in...



PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required.)

UsernamePublicRestriction

Register

SC141576

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel